United Therapeutics's board approves new $2B repurchase authorization; prices $1.5B ASR
Source: SeekingAlpha
2026-03-09 07:37:10 ET
More on United Therapeutics
- United Therapeutics Corporation (UTHR) Presents at TD Cowen 46th Annual Health Care Conference Transcript
- United Therapeutics Corporation (UTHR) Discusses Phase III ADVANCE OUTCOMES Clinical Trial Results in Pulmonary Hypertension Transcript
- United Therapeutics Corporation (UTHR) Discusses Phase III ADVANCE OUTCOMES Clinical Trial Results in Pulmonary Hypertension - Slideshow
- MannKind, Liquidia fall as United Therapeutics mulls new treprostinil formulation
- United Therapeutics targets $4B revenue run rate by 2027 as new product launches approach
Read the full article on Seeking Alpha
For further details see:
United Therapeutics's board approves new $2B repurchase authorization; prices $1.5B ASR
United Therapeutics Corporation
NASDAQ: UTHR
UTHR Trading
5.29% G/L:
$544.175 Last:
330,802 Volume:
$525.86 Open:
UTHR Latest News
March 09, 2026 07:00:00 am
United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
March 03, 2026 07:00:00 am
United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
March 02, 2026 06:30:00 am
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
February 25, 2026 06:30:00 am
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
UTHR Stock Data
$20,237,032,096
38,621,769
0.2%
368
N/A
Biotechnology & Life Sciences
Healthcare
US
Silver Spring
